Queensland Schedule 4 Cosmetic Injectables Compliance
Understand Queensland rules for Schedule 4 clinic stock, custody, telehealth and nurse administration, and how Yooli supports compliant cosmetic clinics.
Three key takeaways
- An ordinary registered nurse cannot independently order, buy or hold general Schedule 4 cosmetic injectable stock for a Queensland clinic.
- Model A uses clinic stock under genuine doctor or nurse practitioner custody and control. Model B uses dispensed, labelled and patient-specific medicines.
- A doctor or nurse practitioner does not need to be continuously onsite for each administration, but genuine clinic connection, lawful prescribing, custody and control, storage, scope and traceability remain essential.
Queensland Schedule 4 Cosmetic Injectables: A Nurse’s Guide to Clinic Stock and Compliance
Queensland cosmetic injectables compliance begins with medicines law. The Medicines and Poisons Act 2019 (Qld) is the primary Act governing regulated activities involving medicines and poisons. The Medicines and Poisons (Medicines) Regulation 2021 (Qld) supplies the detailed rules for authorised persons, purchase orders, possession, prescribing, administration, dispensing, storage, medicine stores and records. Both instruments were checked in their current in-force versions before this article was prepared. [1][2]
The Commonwealth Poisons Standard classifies Schedule 4 medicines as prescription-only medicines. Queensland law then gives that scheduling practical legal effect in Queensland. Cosmetic injectable medicines such as botulinum toxin products and many dermal fillers are therefore not ordinary commercial inventory. Their purchase, possession, storage and use must remain within an authorised clinical pathway. [1][3][4]
For registered nurses, the central point is straightforward. An ordinary registered nurse cannot independently order, buy or hold general Schedule 4 cosmetic injectable stock for a Queensland clinic. A nurse may administer an authorised Schedule 4 medicine on a valid prescription and within the nurse’s competence and scope, but that authority is not the same as an independent authority to acquire or control general clinic stock. [2][4][5]
The law and the regulator’s position
What are often described as Queensland cosmetic nurse regulations sit across legislation, regulatory guidance and professional standards, so it is useful to separate them.
The Act is primary legislation enacted by the Queensland Parliament. The Regulation is subordinate legislation made under authority conferred by the Act. A valid regulation is binding, but its lawful reach is limited by the power given by the authorising Act. Queensland’s legislative scrutiny principles recognise that subordinate legislation should be within the power that allows it to be made and consistent with the policy objectives of the authorising law. If a court determines that subordinate legislation is beyond power or irreconcilably inconsistent with an Act, the Act prevails to the extent of the invalidity or inconsistency. [1][6]
At a system level, the roles are distinct. Queensland Parliament enacts the Act. The Regulation is subordinate legislation made through Queensland’s delegated law-making process under the Act. The TGA administers the Commonwealth scheduling framework and publishes the Poisons Standard. Queensland Health administers and enforces the Queensland medicines laws, while Ahpra and the National Boards regulate registered practitioners and issue professional standards and guidance. [3][4][7]
That principle does not permit a clinic to ignore a regulation, compliance notice or regulator position because it prefers another interpretation. A genuine question about validity, inconsistency or the limits of an official power should be addressed through specific legal advice and the appropriate review process.
Queensland Health’s fact sheets and FAQs explain the Department’s current interpretation and preferred compliance approach. They are important materials, but they are not, by themselves, Acts or regulations. Their legal force depends on the underlying legislation or on an instrument that has been validly given legal effect. Similarly, Ahpra, the Medical Board of Australia and the Nursing and Midwifery Board of Australia regulate practitioners under the National Law and publish professional standards and guidelines. Those materials do not themselves create a Queensland authority to buy, possess or prescribe medicines, although they remain relevant to competence, professional conduct, telehealth and scope of practice. [4][7][8][12]
How Queensland Health is empowered to regulate
The Medicines and Poisons Act establishes a substantial monitoring and enforcement framework, but each power must be exercised within the conditions and limits stated in the Act.
Sections 129 to 131 provide for inspectors and identify their functions, including investigating, monitoring and enforcing compliance. Section 140 permits entry to a professional practice place in specified circumstances, including when the place is open for business or otherwise open for entry. It does not create an unlimited power to enter residential parts of premises. [1]
After lawful entry, sections 158 and 159 allow an inspector to search, inspect, examine or film parts of the place and things at the place, take samples, copy documents and require reasonable assistance, including assistance to produce records or information. Sections 177 and 180 provide additional document-production and information-gathering powers in the circumstances stated in those provisions. [1]
Sections 108 to 110 allow the chief executive or an inspector to issue a compliance notice where the statutory criteria are met, require reasonable rectification steps and treat unjustified non-compliance with the notice as an offence. These powers matter because a clinic may need to demonstrate its position through records, not merely through verbal assurances. A registered nurse or clinic manager should expect that purchasing evidence, prescriptions, administration records, storage arrangements and stock traceability may be examined. [1]
Model A and Model B: the two permitted pathways
Queensland Health describes two compliant business models for cosmetic injectable clinics. They are commonly referred to as Model A and Model B. [4][5]
Model A: clinic stock under authorised practitioner custody and control
Under Model A clinic stock, a medical practitioner or nurse practitioner buys the Schedule 4 medicines as stock for use at the clinic. The authorised practitioner must genuinely practise at, or have the required practising connection with, that clinic and must exercise exclusive custody and control of the general stock, or joint custody and control only with another authorised medical practitioner or nurse practitioner. [4][5]
The Act defines possession by reference to custody or control and recognises that possession can be joint. In practice, the Model A question is whether the authorised practitioner has a real and continuing ability to govern the medicines, not whether their name appears on a document while somebody else independently controls the stock. [1][4]
A registered nurse does not independently buy or control the general stock. The nurse may access and possess a dose for the authorised purpose of preparing and administering it to an identified patient on a valid prescription. The nurse must administer in accordance with that prescription and within the authority in Schedule 7 of the Regulation. When the Model A requirements are genuinely met, the remaining stock can lawfully stay at the clinic as clinic stock under the authorised practitioner’s custody and control. [2][4]
Model B: patient-specific dispensed medicines
Under Model B dispensed medicines, a medical practitioner or nurse practitioner consults with the patient, including by telehealth where clinically appropriate, and writes a prescription for dispensing. An authorised pharmacist or medical practitioner then dispenses and labels the medicine for that individual patient. The dispensed medicine may be sent directly to the clinic for administration by an authorised nurse. [4][5]
Model B does not mean that no medicine is ever physically present at the clinic. It means that any medicine present under this pathway is a dispensed, labelled and patient-specific medicine, rather than undispensed general clinic stock. Queensland Health’s March 2026 FAQ expressly states that registered nurses may hold individually dispensed medicines for individual clients even though they cannot possess general Schedule 4 stock for use in their clinics. [5]
The practical comparison is therefore simple. Model A involves general clinic stock held under genuine doctor or nurse practitioner custody and control. Model B involves patient-specific medicine that has already been lawfully dispensed.
This is not an onsite doctor debate
Queensland law does not require a doctor or nurse practitioner to stand inside the clinic during every administration. Queensland Health’s current consumer guidance states that a doctor or nurse practitioner need not be onsite at the moment the medicine is administered, provided the medicine has been prescribed specifically for the patient. The Department also confirms that the Act and Regulation do not prohibit telehealth consultations for lawful prescribing. [4][9]
That does not make physical presence irrelevant to Model A. Queensland Health says it will consider the overall connection between the doctor or nurse practitioner and the clinic, together with physical presence appropriate to that individual clinic, when assessing custody and control. It identifies matters such as whether the practitioner routinely practises there, has independent access and is represented as practising from the clinic. A nominal appointment, contract or title is not enough if the arrangement does not operate genuinely in practice. [4][5]
The more useful questions are these: Who lawfully bought the stock? Who has custody or control of the general stock? Does the authorised practitioner genuinely practise at or in connection with the clinic? Who governs access, storage and medicines management? Is every administration supported by a lawful patient-specific prescription? Can each medicine be traced and audited? Is the nurse acting within lawful authority, competence and scope?
What Queensland Health may examine during compliance activity
Queensland Health states that it undertakes inspections and audits to support compliance. Its March 2026 FAQ arose from routine compliance activities and says the Department will continue to engage with industry and work with clinics, wholesalers and prescribers. It does not establish a fixed audit interval for every clinic. [5][9]
At a high level, a compliance review may examine lawful purchasing and supply, evidence of authorised custody and control, storage and cold-chain arrangements, prescriptions, administration records, access to medicine stores, batch and expiry traceability, incident reporting, stock reconciliation and corrective action. It may also consider practitioner registration, credentialing, competence and whether the clinic model described on paper is the model operating in practice. These are reasonable audit-readiness priorities drawn from the statutory framework, Queensland Health’s published focus and Yooli’s governance standards. [1][2][4]
A prudent clinic should assume its arrangements and records may need to withstand scrutiny at any time. Governance should be visible in daily practice.
Why this matters personally to registered nurses
Registered nurses are accountable for their own conduct, even when a platform, clinic owner or prescriber has designed the broader workflow.
A nurse may face medicines-law or professional risk by independently ordering or buying general Schedule 4 stock, exercising independent control over clinic inventory, administering without a valid prescription, accepting an unverified supply pathway, practising outside competence or scope, or failing to create accurate and traceable records. Risk also increases where a clinic cannot show who genuinely controls the stock or where the operating model is inconsistent with the documents presented to staff and regulators. [2][4][7]
These risks are manageable when a properly constructed model aligns legal authority, clinical governance and daily practice.
How Yooli supports a Queensland Model A clinic
Yooli is a compliance-first platform and compliance solution designed specifically for the Australian cosmetic industry by professionals with experience in cosmetic medicine, clinical governance, healthcare administration and regulation.
The Yooli cosmetic clinics platform and its Queensland framework are designed to support Model A clinics that lawfully hold Schedule 4 clinic stock. At a high level, the framework brings together accountable authorised-practitioner governance, documented medicines policies, clinic-level oversight, traceability, credentialing, incident management and audit readiness. Yooli’s public platform also connects structured scripting, patient and clinic records, stock workflows, role-based access, compliance protocols, audit trails, training and accreditation support. [10][11]
Queensland Health describes an SMP as a document for managing known and foreseeable risks at a regulated place, and where an SMP applies, compliance with it forms part of the authorised way. A statutory SMP requirement depends on the type of place or any authority condition. Yooli uses a Queensland-specific SMP as a central governance control for its Model A framework. [11][17]
The Queensland Model A framework has been externally reviewed by experienced legal advisers against the Medicines and Poisons Act and the Medicines and Poisons (Medicines) Regulation. Its implementation has also been subject to external compliance assurance. The April 2026 review supplied in Yooli’s source pack recorded an overall assessment of “Full Compliance” for the reviewed clinic and the matters within that review’s scope, while also identifying limited areas for improvement. That statement is confined to the reviewed clinic, framework implementation and audit scope. It is not a claim that every current or future Yooli user is automatically compliant. [12][13]
Yooli’s framework assigns accountable clinic-stock governance to an authorised medical practitioner or nurse practitioner and supports registered nurses through a structured environment rather than treating cosmetic scripting as an isolated transaction. Its supplied standards address lawful administration, patient-specific prescribing, practitioner credentialing, medicines oversight, records and ongoing compliance assurance at a governance level. The proprietary mechanics used to implement those controls are not set out in this article. [11][14][15][16]
Software alone cannot guarantee compliance. Each clinic and practitioner must still follow the applicable framework, maintain current registration and competence, act within scope, complete required records, respond to incidents and ensure that the documented custody-and-control model is the model operating in practice.
For a nurse choosing a cosmetic clinic compliance platform, the relevant question is not simply whether a script can be generated. It is whether the platform can demonstrate a Queensland-specific framework for Schedule 4 clinic stock, credible governance, external review and practical audit readiness.
When choosing a cosmetic clinic compliance platform, why accept avoidable uncertainty when you can ask for evidence of Queensland-specific governance, external review and audit readiness?
References
- Medicines and Poisons Act 2019 (Qld), current reprint from 23 October 2025.
- Medicines and Poisons (Medicines) Regulation 2021 (Qld), current reprint from 1 March 2026.
- Therapeutic Goods Administration, The Poisons Standard, including the Therapeutic Goods (Poisons Standard, June 2026) Instrument 2026.
- Queensland Health, Medicines in beauty treatment and cosmetic injectable businesses, including the current cosmetic injectables fact sheet.
- Queensland Health, FAQ, Medicines in beauty treatment/cosmetic businesses, March 2026.
- Queensland Parliament, Fundamental Legislative Principles.
- Ahpra and the National Boards, Guidelines for registered health practitioners who perform non-surgical cosmetic procedures, effective 2 September 2025.
- Medical Board of Australia, Guidelines: Telehealth consultations with patients.
- Queensland Health, Beginner-friendly guide to cosmetic injectables, published 18 March 2026.
- Yooli Cosmetic Clinics framework, current public platform description.
- Yooli Substance Management Plan (SMP) QLD
- External legal advice to Yooli regarding the Queensland Model A framework, dated 22 January 2026
- April 2026 external compliance assurance review. The review outcome is relied on only in relation to the reviewed clinic and stated scope.
- Yooli Video Medical Consultation for Consultation, Authorisation, Administration and Prescription of Schedule 4 Poisons framework
- Yooli Cosmetic Nurse Injector Administering Schedule 4 Medicines framewok
- Yooli Cosmetic Nurse Injector Credentialing and Scope of Practice Policy framework
- Queensland Health, Substance management plans, together with the Departmental Standard for Substance Management Plans for Medicines.
- Queensland Health, Beginner-friendly guide to cosmetic injectables, June 2025 supplied version. This version was reviewed for comparison only. The current March 2026 public material prevailed.
- Earlier external legal and compliance reports
